UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~November~~May 41, ~~2024~~2025

UNITED HEALTH PRODUCTS, INC.

(Exact name of registrant as specified in its charter)

Nevada

000-27781

84-1517723

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

520 Fellowship Road, Suite #D-406

Mt. Laurel, NJ 08054

(Address of Principal Executive Offices) (Zip Code)

(475) 755-1005

Registrant’s telephone number, including area code

___________________________________________________

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Item 8.01. Other Events.

On ~~November~~May 41, ~~2024~~2025, ~~the~~ United Health Products, Inc. (the “Company”) issued a press release announcing anthat ~~update~~its oncommon ~~the~~stock ~~FDA’s~~had ~~Premarket~~been ~~Approval~~upgraded ~~application~~from ~~for~~the OTC Pink to the ~~company’s~~OTCQB ~~HemoStyp®~~Venture ~~Gauze~~Market.

The press release also provided an update regarding the Company’s Premarket Approval application with the U.S. Food and Drug Administration for its CelluSTAT® gauze product. We refer you to the risk factors in Part I Item 1A in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and in Part II Item 1A of the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2025 for a discussion of the risks relating to our Premarket Approval application.

A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.

We refer you to the risk factors in Part II Item 1A of the company’s Quarterly Report on Form 10-Q for the period ended June 30, 2024 for a discussion of the risks relating to our Premarket Approval application.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press release, dated ~~November~~May 41, ~~2024~~2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL Document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

	United Health Products, Inc.
Dated: November 6, 2024	By:	/s/ Brian Thom
Dated: May 8, 2025	By:	/s/ Brian Thom
		Brian ThomChief Executive Officer

Filing Compare · United Health Products, Inc.